GenScript is the world leader in biotechnology reagent service industry. Established in 2002 in New Jersey, United States, the company was the first to commercialize gene synthesis and successfully establish fully integrated capabilities for custom peptide synthesis, protein expression and engineering, custom antibody development and engineering, animal model development, in vitro/in vivo pharmacology as well as a variety of catalogue products.
GenScript has now expanded its business into immunotherapy, CDMO, laboratory equipment, and microbial industry to further fulfill its mission in making people and nature healthier through biotechnology. GenScript has also established open and innovative technology-driven platforms and GMP facilities for pre-clinical drug discovery and pharmaceutical products development along with a completed industrial microbial research, development and industrialization platform for enzyme screening, genetic engineering, protein engineering, and fermentation process optimization and research application.
With more than 2,000 employees holding advanced degrees, GenScript has been able to develop advanced infrastructure in R&D, production, packaging and shipment in order to make research easy for scientists.
For example, GenScript’s proprietary GenPlus™ Next-Gen HT gene synthesis, PepPower™ automatic microwave-assisted express peptide synthesis, high-throughput gene-to-antibody expression platform, and the MonoRab™ super sensitive rabbit monoclonal antibody technology platforms has enabled GenScript to provide high-quality custom reagents at competitive prices for a variety of research needs. Because of these competencies, one out of four genes synthesized worldwide is done by GenScript.
GenScript was able to deliver the synthetic Zika virus gene in 4 days, and were the only commercial entity to be invited to participate in the Yeast 2.0 genome project. Also, GenScript’s stringent quality control and smart ordering system allow them to provide high-quality reagents in an efficient manner.
Moreover, GenScript now offers guarantees on aspects of many services customers rely on the most. Their extensive platforms enable target identification for drug discovery and development, and they make IND filing very easy for bench-to-bedside researchers.
GenScript’s proprietary technology platforms in a variety of domains make them very competitive in the biologics space. With core competence in gene synthesis, GenScript can synthesize any sequence at any length or complexity for all biologics-focused purposes.
GenScript’s capabilities for recombinant protein expression in a variety of host organisms, along with antibody engineering and production capabilities in major host animals, have proven to be effective in the development of novel biologics. All of GenScript’s biologics-focused platforms are highly customizable, ensuring that the specific needs of each client’s project are addressed.
The capacity of GenScript’s platform for high-throughput and scalable production also helps our customers to move through the optimization process quickly but efficiently. Two out of many of our success stories in this regard are the successful generation and application of a therapeutic antibody for the treatment of multiple myeloma, and generation of a novel HIV vaccine with high efficiency and low toxicity.